Intelgenx ED results positive

IntelGenx (TSX-V:IGX) has completed a pilot study that indicates its oral film, INT007, is bioequivalent to a leading branded tablet containing a phosphodiesterase type 5 (PDE-5) inhibitor for the treatment of erectile dysfunction. “This is the second VersaFilm project that we progressed into the clinic, and the second VersaFilm project that has yielded positive bioequivalence [...]

IntelGenx in commercialization pact with RedHill

IntelGenx (TSX-V:IGX) has entered into a co-development and commercialization agreement with RedHill Biopharma of Israel to develop IntelGenx’s first product from its VersaFilm technology for rapid relief of migraine. Under the accord, RedHill has obtained certain exclusive worldwide rights to market and sell IntelGenx’ rapidly dissolving anti-migraine oral film product. In exchange, IntelGenx will receive [...]

IntelGenx arranging $2.5 million private placement

IntelGenx Technologies (TSX-V:IGX) has retained Bolder Investment Partners to complete a private placement in Canada to raise up to $2.5 million by issuing units priced at 40 cents apiece. Each unit will consist of one common share and one warrant that can be exercised to purchase an additional common share of the company for 50 [...]

IntelGenx to file NDA amendment in first quarter

IntelGenx Technologies (TSX-V:IGX) has met with the FDA to discuss a complete response letter received in February about its new drug application for its antidepressant CPI-300 and expects to file an amendment to the NDA in the first quarter of 2011. CPI-300 is a novel, high strength of Bupropion HCl, the active ingredient in Wellbutrin [...]

IntelGenx buys back CPI-300 from Cary Pharma

IntelGenx (TSX-V:IGX; OTCBB:IGXT) has acquired full rights to CPI-300, a high-strength formulation of the active ingredient in the antidepressant Wellbutrin XL, from Cary Pharmaceuticals after the companies agreed to terminate their 2007 collaborative development agreement. In addition to certain potential pre-commercialization payments and in the event of CPI-300 being commercialized, IntelGenx will pay Cary 10% [...]

IntelGenx to license anti-migraine film product

IntelGenx (TSX-V:IGX) has signed a binding term-sheet with closely held RedHill Biopharma of Israel to co-develop and license IntelGenx’s rapidly dissolving anti-migraine oral film product based on its VersaFilm technology. “We are excited to have concluded our first, of what we believe to be many future, thin film partnerships,” CEO Dr. Horst Zerbe said in [...]

IntelGenx gets bupropion patent in U.S.

IntelGenx (TSX-V:IGX) has received a U.S. patent  for CPI-300, a new formulation of bupropion hydrochloride, the active ingredient in Wellbutrin XL, covering the formulation of pharmaceutical tablets containing sustained-release granules of bupropion HCl distributed in a sustained-release matrix. “The successful issuance of this patent provides formidable intellectual property protection for CPI-300 and further strengthens our [...]

Cannasat batting hot streak in its CNS turnaround

First time up to bat, Anthony Giovinazzo hit what he calls a triple.  He followed that up with a single.  Now, he’s looking to park one in the bleachers. Newly installed in the executive suite at Cannasat Therapeutics (TSX-V:CTH) last November, Mr. Giovinazzo’s mandate is to rebrand the company, founded in 2004 by Moses Znaimer [...]

IntelGenx and Cannasat in Relivar licensing pact

IntelGenx (TSX-V:IGX) and Cannasat Therapeutics (TSX-V:CTH) have entered into a letter of intent that would give IntelGenx a 50% ownership stake and an exclusive worldwide licence to develop and commercialize Cannasat’s Relivar drug candidate. Under the accord, the two companies will negotiate an exclusive worldwide licence that should result in IntelGenx assuming sole product development [...]

IntelGenx gets FDA complete response letter

IntelGenx Technologies (TSX-V:IGX) has received a complete response letter from the FDA for its new drug application of its antidepressant, CPI-300, which it developed with Cary Pharmaceuticals. The FDA letter lists two main issues that need to be addressed in order to obtain approval, “namely the qualification of a commercial manufacturing site and the food [...]